AnaptysBio (ANAB) has drawn investor attention after recent share price moves, with the stock last closing at US$56.61. The company focuses on immunology therapeutics for autoimmune and inflammatory diseases.
See our latest analysis for AnaptysBio.
Recent trading has been choppy. The stock has a 1-day share price return of 3.36% and 7-day share price return of 5.50%. However, it is down 14.73% over 30 days, while the year-to-date share price return is 25.94% and the 1-year total shareholder return is very large. This points to strong longer term momentum despite recent volatility.
If AnaptysBio’s recent swings have you thinking about where else growth stories may emerge, it could be worth lining up a few new ideas through the 43 healthcare AI stocks.
After AnaptysBio’s sharp gains over the past year, the stock now trades at a sizeable discount to both analyst targets and an estimated intrinsic value. Is the market being disciplined about risk, or overly cautious on the upside potential?
Most Popular Narrative: 37.1% Undervalued
Compared with the last close at $56.61, the most followed narrative on AnaptysBio points to a fair value of $90, which is a sizeable gap.
ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock.
Want to understand why this narrative assigns such a premium to AnaptysBio? The story focuses on potential future royalty cash flows and higher margins, along with assumptions for revenue growth and profitability. The lawsuit angle adds another potential source of upside that is fully reflected in the $90 fair value used in this narrative.
Result: Fair Value of $90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh real risks. The GSK litigation could conclude with limited benefits, and royalty or clinical outcomes may differ from expectations.
Find out about the key risks to this AnaptysBio narrative.
Next Steps
With optimism around AnaptysBio’s rewards running through this discussion, it makes sense to move quickly and test the numbers yourself using the 2 key rewards.
Looking for more investment ideas beyond AnaptysBio?
If AnaptysBio has sharpened your focus on new opportunities, you can build on that momentum by scanning fresh stock ideas now so you are not reacting after markets move.
- Target potential mispricings by checking companies that appear attractively valued on fundamentals through the 52 high quality undervalued stocks.
- Prioritise resilience by filtering for companies with stronger balance sheets and healthier financial profiles using the solid balance sheet and fundamentals stocks screener (48 results).
- Hunt for less crowded opportunities by reviewing the screener containing 21 high quality undiscovered gems before other investors start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com